Building high-resolution synthetic lethal networks: a 'Google map' of the cancer cell.

The most commonly used therapies for cancer involve delivering high doses of radiation or toxic chemicals to the patient that also cause substantial damage to normal tissue. To overcome this, researchers have recently resorted to a basic biological concept called 'synthetic lethality' (SL) that takes advantage of interactions between gene pairs. The identification of SL interactions is of considerable therapeutic interest because if a particular gene is SL with a tumor-causing mutation, then the targeting that gene carries therapeutic advantages. Mapping these interactions in the context of human cancer cells could hold the key to effective, targeted cancer treatments. In this review, we cover the recent advances that aim to identify these SL interactions using unbiased genetic screens.

[1]  Yilong Li,et al.  Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library , 2013, Nature Biotechnology.

[2]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[3]  Yiyu Dong,et al.  Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. , 2010, Cancer research.

[4]  K. McManus,et al.  Synthetic Genetic Targeting of Genome Instability in Cancer , 2013, Cancers.

[5]  Xiangwei Wu,et al.  An intermittent approach for cancer chemoprevention , 2011, Nature Reviews Cancer.

[6]  A. Krasnitz,et al.  An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer , 2008, Cell.

[7]  Brady Bernard,et al.  Synthetic lethal screens as a means to understand and treat MYC-driven cancers. , 2014, Cold Spring Harbor perspectives in medicine.

[8]  Roland Arnold,et al.  A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities , 2013, Molecular systems biology.

[9]  C. Chuong,et al.  SnapShot: Branching Morphogenesis , 2014, Cell.

[10]  Wolfgang Huber,et al.  Mapping of signaling networks through synthetic genetic interaction analysis by RNAi , 2011, Nature Methods.

[11]  M. Yaffe,et al.  A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. , 2013, Cell reports.

[12]  Nevan J Krogan,et al.  High-throughput genetic interaction mapping in the fission yeast Schizosaccharomyces pombe , 2007, Nature Methods.

[13]  P. Hieter,et al.  Saccharomyces cerevisiae Genetics Predicts Candidate Therapeutic Genetic Interactions at the Mammalian Replication Fork , 2013, G3: Genes | Genomes | Genetics.

[14]  Gary D Bader,et al.  The Genetic Landscape of a Cell , 2010, Science.

[15]  R. Barrangou,et al.  CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes , 2007, Science.

[16]  Joshua M. Stuart,et al.  A global analysis of genetic interactions in Caenorhabditis elegans , 2007, Journal of biology.

[17]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[18]  C. Grandori A high-throughput siRNA screening platform to identify MYC-synthetic lethal genes as candidate therapeutic targets. , 2013, Methods in molecular biology.

[19]  Lucas Pelkmans,et al.  A Hierarchical Map of Regulatory Genetic Interactions in Membrane Trafficking , 2014, Cell.

[20]  A. Giaccia,et al.  Harnessing synthetic lethal interactions in anticancer drug discovery , 2011, Nature Reviews Drug Discovery.

[21]  Jacques Colinge,et al.  A chemical genetic screen reveals a resistance mechanism to PI3K inhibitors in cancer , 2011, Nature chemical biology.

[22]  M. Barbacid,et al.  RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.

[23]  Kevin R Brown,et al.  Essential gene profiles in breast, pancreatic, and ovarian cancer cells. , 2012, Cancer discovery.

[24]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .

[25]  A. Rose,et al.  Synthetic Lethal Interactions Identify Phenotypic “Interologs” of the Spindle Assembly Checkpoint Components , 2007, Genetics.

[26]  S. Magdaleno,et al.  Discovery of a Dicer-Independent, Cell-Type Dependent Alternate Targeting Sequence Generator: Implications in Gene Silencing & Pooled RNAi Screens , 2014, PloS one.

[27]  Ian Collins,et al.  New approaches to molecular cancer therapeutics , 2006, Nature chemical biology.

[28]  Patrick J. Paddison,et al.  A resource for large-scale RNA-interference-based screens in mammals , 2004, Nature.

[29]  D. Durocher,et al.  Significant conservation of synthetic lethal genetic interaction networks between distantly related eukaryotes , 2008, Proceedings of the National Academy of Sciences.

[30]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[31]  Hiroshi Nishimasu Crystal Structure of Cas9 , 2015 .

[32]  F. Zhang,et al.  CRISPR/Cas9 for genome editing: progress, implications and challenges. , 2014, Human molecular genetics.

[33]  Andreas Schlicker,et al.  Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. , 2014, Cell reports.

[34]  Yolanda T. Chong,et al.  A picture is worth a thousand words: Genomics to phenomics in the yeast Saccharomyces cerevisiae , 2009, FEBS letters.

[35]  Paul Shinn,et al.  Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. , 2012, Cancer cell.

[36]  P. Hieter,et al.  Establishing genetic interactions by a synthetic dosage lethality phenotype. , 1996, Genetics.

[37]  Aaron N. Chang,et al.  Functional genomics identifies therapeutic targets for MYC-driven cancer , 2012, Proceedings of the National Academy of Sciences.

[38]  Alan Ashworth,et al.  Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. , 2014, Cancer research.

[39]  P. Hieter,et al.  Synthetic Lethal Targeting of Superoxide Dismutase 1 Selectively Kills RAD54B-Deficient Colorectal Cancer Cells , 2013, Genetics.

[40]  P. Hieter,et al.  An Evolutionarily Conserved Synthetic Lethal Interaction Network Identifies FEN1 as a Broad-Spectrum Target for Anticancer Therapeutic Development , 2013, PLoS genetics.

[41]  Wolfgang Huber,et al.  Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping , 2013, Nature Methods.

[42]  Jef D Boeke,et al.  dSLAM analysis of genome-wide genetic interactions in Saccharomyces cerevisiae. , 2007, Methods.

[43]  F. Ciccarelli,et al.  Recessive cancer genes engage in negative genetic interactions with their functional paralogs. , 2013, Cell reports.

[44]  Anne E Carpenter,et al.  A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen , 2006, Cell.

[45]  Nathan T. Ross,et al.  A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells , 2012, ACS medicinal chemistry letters.

[46]  Nathan T. Ross,et al.  STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability , 2012, Proceedings of the National Academy of Sciences.

[47]  Jeff Piotrowski,et al.  A comparative genomic approach for identifying synthetic lethal interactions in human cancer. , 2013, Cancer research.

[48]  Stephen H. Friend,et al.  Potential of the Synthetic Lethality Principle , 2013, Science.

[49]  P Manimaran,et al.  Identification of synthetic lethal pairs in biological systems through network information centrality. , 2013, Molecular bioSystems.

[50]  P. Reaper,et al.  Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. , 2011, Nature chemical biology.

[51]  J. C. Love,et al.  In vivo discovery of immunotherapy targets in the tumour microenvironment , 2014, Nature.

[52]  L. Zender,et al.  Deregulated MYC expression induces dependence upon AMPK-related kinase 5 , 2012, Nature.

[53]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[55]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[56]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[57]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[58]  Grant W. Brown,et al.  Chemical–Genetic Profiling of Imidazo[1,2-a]pyridines and -Pyrimidines Reveals Target Pathways Conserved between Yeast and Human Cells , 2008, PLoS genetics.

[59]  J. McCarter,et al.  STK33 kinase activity is nonessential in KRAS-dependent cancer cells. , 2011, Cancer research.

[60]  Ji Luo,et al.  A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis , 2012, Science.

[61]  J. Settleman,et al.  Targeting the RAF-MEK-ERK pathway in cancer therapy. , 2009, Cancer letters.

[62]  L. Chin,et al.  Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer , 2012, Nature.

[63]  Richard Simon,et al.  Identification of potential synthetic lethal genes to p53 using a computational biology approach , 2013, BMC Medical Genomics.

[64]  T. Eguchi,et al.  RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene , 2007, Oncogene.

[65]  Sridhar Ramaswamy,et al.  Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells , 2009, Cell.

[66]  Ben Lehner,et al.  Evolutionary plasticity of genetic interaction networks , 2008, Nature Genetics.

[67]  Curt I Civin,et al.  Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. , 2013, Blood.

[68]  B. Andrews,et al.  Systematic mapping of genetic interaction networks. , 2009, Annual review of genetics.

[69]  M. Piccart,et al.  First-Line Treatment of Metastatic Breast Cancer , 2006 .

[70]  I. Mellinghoff,et al.  Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer , 2006, Nature Medicine.

[71]  C. Grandori,et al.  Functional genomics to identify unforeseen cancer drug targets. , 2013, Future oncology.

[72]  P. Hieter,et al.  Synthetic lethal genetic interactions that decrease somatic cell proliferation in Caenorhabditis elegans identify the alternative RFC CTF18 as a candidate cancer drug target. , 2009, Molecular biology of the cell.

[73]  Malini Guha PARP inhibitors stumble in breast cancer , 2011, Nature Biotechnology.

[74]  Reuven Agami,et al.  A large-scale RNAi screen in human cells identifies new components of the p53 pathway , 2004, Nature.

[75]  Hong Liu,et al.  Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase , 2010, Proceedings of the National Academy of Sciences.

[76]  Frederick S. Vizeacoumar,et al.  Systematic exploration of essential yeast gene function with temperature-sensitive mutants , 2011, Nature Biotechnology.

[77]  Yang Bian,et al.  Synthetic genetic array screen identifies PP2A as a therapeutic target in Mad2-overexpressing tumors , 2014, Proceedings of the National Academy of Sciences.

[78]  Hong Wu,et al.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[79]  Franco J. Vizeacoumar,et al.  Integrating high-throughput genetic interaction mapping and high-content screening to explore yeast spindle morphogenesis , 2010, The Journal of cell biology.

[80]  Sourav Bandyopadhyay,et al.  Quantitative genetic-interaction mapping in mammalian cells , 2013, Nature Methods.

[81]  C. Kemp,et al.  Synthetic lethality between mutation in Atm and DNA-PKcs during murine embryogenesis , 2001, Current Biology.

[82]  Bhavneet Bhinder,et al.  Systematic analysis of RNAi reports identifies dismal commonality at gene-level and reveals an unprecedented enrichment in pooled shRNA screens. , 2013, Combinatorial chemistry & high throughput screening.

[83]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.

[84]  Eytan Ruppin,et al.  Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality , 2014, Cell.

[85]  B. Druker,et al.  Applying the discovery of the Philadelphia chromosome. , 2007, The Journal of clinical investigation.

[86]  J. Blenis,et al.  An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[87]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[88]  Michael T. McManus,et al.  A Systematic Mammalian Genetic Interaction Map Reveals Pathways Underlying Ricin Susceptibility , 2013, Cell.

[89]  C. Roberts,et al.  Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers , 2014, Proceedings of the National Academy of Sciences.

[90]  L. Hartwell,et al.  Integrating genetic approaches into the discovery of anticancer drugs. , 1997, Science.

[91]  Grant W. Brown,et al.  Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map , 2007, Nature.

[92]  René Bernards,et al.  A Missing Link in Genotype-Directed Cancer Therapy , 2012, Cell.

[93]  Mari Mino-Kenudson,et al.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.

[94]  P. Hieter,et al.  Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing , 2009, Proceedings of the National Academy of Sciences.

[95]  Anna Marie Mulligan,et al.  JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer , 2008, Breast Cancer Research and Treatment.

[96]  Michael J. Emanuele,et al.  A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.